Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventional

Evaluation of a Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment in an Underserved Gynecology Population

NCT ID: NCT05562778Sponsor: Weill Medical College of Cornell UniversityLast updated: 2025-07-28

Summary

In this study, the investigators aim to compare a mobile health platform, known as a 'chatbot,' that leverages artificial intelligence and natural language processing to scale communication, to 'usual care' that patients would receive. This comparison will enable the investigators to determine if the chatbot system can improve rates of recommendation for genetic testing among patients at elevated risk of harboring a familial cancer syndrome in an all-Medicaid gynecology clinic. Furthermore, the investigators aim to evaluate facilitators of inequity in regard to patient access to and utilization of genetic testing services.

Arms & interventions

  • OtherChatbot

    A chatbot is a software program designed to simulate human conversation, typically via text. Chatbots utilize natural language processing to gather patient data, anticipate questions, and predict responses. In this study, the Chatbot will simulate a text-like conversation with patients via a smartphone and use this platform to deal with the time-consuming nature of family history collection. The chatbots can then triage the collected family history against medical guidelines to determine which patients warrant genetic testing. For those patients meeting criteria for genetic testing, the chatbot can offer pre-test education and assist physicians with ordering genetic testing for interested patients meeting high-risk criteria.

Outcome measures

Primary

  • Proportion recommended genetic testing

    The proportion of high-risk patients that are recommended genetic testing for familial cancer syndromes in the chatbot vs. usual care arms.

    Time frame: 2 years

Secondary

  • Proportion completed recommended genetic testing

    Time frame: 2 years

  • Facilitator of inequity in the utilization of genetic services

    Time frame: 2 years

  • Facilitator of inequity in the utilization of genetic services

    Time frame: 2 years

  • Facilitator of inequity in the utilization of genetic services

    Time frame: 2 years

  • Facilitator of inequity in the utilization of genetic services

    Time frame: 2 years

  • Facilitator of inequity in the utilization of genetic services

    Time frame: 2 years

  • Facilitator of inequity in the utilization of genetic services

    Time frame: 2 years

  • Facilitator of inequity in the utilization of genetic services

    Time frame: 2 years

  • Barriers to genetic testing

    Time frame: 2 years

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: Yes
Inclusion Criteria: * 8 years of age or older. * Scheduled for a New Patient appointment in the gynecology clinic. Speaks and reads in English. * Access to a telephone with texting capacity. * Has not had prior genetic testing for hereditary cancer syndromes. Exclusion Criteria: * Under 18 years of age * Has had previous genetic testing for hereditary cancer syndromes * Does not read/speak in English * Does not have access to a phone with texting capabilities

Study locations (4)

NYP Brooklyn Methodist Hospital

Brooklyn, New York, 11215

Recruiting
Denise Howard, MD, MPH · Contact
Michael Kim, MD · Contact
Denise Howard, MD, MPH · Principal Investigator

NYP Lower Manhattan Hospital

New York, New York, 10038

Recruiting
Julia Cron, MD, FACOG · Contact
Julia Cron, MD, FACOG · Principal Investigator

Weill Cornell Medicine

New York, New York, 10065

Recruiting
Melissa K Frey, MD, MS · Contact
Isabelle Chandler · Contact
Melissa K Frey, MD · Principal Investigator

NYP Medical Group Queens

Queens, New York, 11375

Recruiting
David Fishman, MD · Contact
David Fishman, MD · Principal Investigator

References

  • Bull LE, Webster EM, McDougale A, Howard D, Ahsan MD, Levi S, Grant B, Chandler I, Christos P, Sharaf RN, Frey MK. Protocol for Health Risk Information Technology-Assisted Genetic Evaluation (HeRITAGE): a randomised controlled trial of digital genetic cancer risk assessment in a diverse underserved gynaecology clinic. BMJ Open. 2024 Sep 5;14(9):e082658. doi: 10.1136/bmjopen-2023-082658.(PubMed)
Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment | Cancerify